Lafora Disease Clinical Trial
Official title:
Intravenous VAL-1221 Lafora Expanded Access Protocol (LEAP)
Only qualified physicians treating a Lafora Disease patient may request VAL-1221 Expanded Access treatment under the Parasail Lafora Expanded Access Protocol (LEAP). According to FDA guidance, this protocol can enroll up to 10 patients. However, individual patient inclusion will ultimately be dependent on protocol eligibility, site geography, treatment requirements, and available supply of the investigational therapy. Inquiring physicians can submit a request by contacting the Central Contact personnel listed below in Contacts/Locations.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03876522 -
Natural History and Functional Status Study of Patients With Lafora Disease
|
||
| Completed |
NCT00007124 -
Ketogenic Diet in Lafora Disease
|
N/A |